These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 5523796)

  • 1. The modifying influence of L-dopa on the physical therapy program in Parkinson's disease.
    Blonsky ER; Minnigh EC
    Prog Phys Ther; 1970; 1(1):55-74. PubMed ID: 5523796
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical study of L-dopa in Parkinson's disease].
    Franken L; Noel G; Lhoas JP; Meyers C; Noel P; Ectors M
    Brux Med; 1972 Dec; 52(12):851-60. PubMed ID: 4575350
    [No Abstract]   [Full Text] [Related]  

  • 3. L-DOPA treatment for Parkinsonism: analysis of functional improvement.
    Jonas S
    Arch Phys Med Rehabil; 1971 Dec; 52(12):560-2. PubMed ID: 5136441
    [No Abstract]   [Full Text] [Related]  

  • 4. Observations on patients with Parkinson's disease treated with L-dopa. I. Trial and evaluation of L-dopa therapy.
    van Wieringen A; Wright J
    S Afr Med J; 1972 Sep; 46(35):1262-6. PubMed ID: 4638222
    [No Abstract]   [Full Text] [Related]  

  • 5. Quantitative measurements of L-dopa therapy in Parkinson's disease.
    Webster DD
    Trans Am Neurol Assoc; 1969; 94():348-50. PubMed ID: 5374483
    [No Abstract]   [Full Text] [Related]  

  • 6. [L-Dopa therapy in Parkinson's disease. A double-blind study].
    Worm-Petersen J; Dupont E; Mikkelsen B
    Ugeskr Laeger; 1971 Nov; 133(47):2321-6. PubMed ID: 4944651
    [No Abstract]   [Full Text] [Related]  

  • 7. L-dopa: effect on highest integrative functions in Parkinsonism.
    Guthrie TC; Dunbar HS; Weider A
    Trans Am Neurol Assoc; 1970; 95():250-2. PubMed ID: 5514382
    [No Abstract]   [Full Text] [Related]  

  • 8. L-dopa and amantadine hydrochloride in Parkinson's disease.
    Parkes JD; Zilkha KJ; Knill-Jones RP; Clements PJ; Baxter R
    Int Z Klin Pharmakol Ther Toxikol; 1971 Apr; 4(3):356-60. PubMed ID: 4931417
    [No Abstract]   [Full Text] [Related]  

  • 9. Quantitative effects of L-dopa on different types of movements and muscle tone in Parkinsonian patients.
    Knutsson E; Mårtensson A
    Scand J Rehabil Med; 1971; 3(3):121-30. PubMed ID: 5156174
    [No Abstract]   [Full Text] [Related]  

  • 10. [The treatment of Parkinson's syndrome with L-dopa].
    Völler GW; Kerstan J
    Nervenarzt; 1970 Mar; 41(3):138-44. PubMed ID: 5447886
    [No Abstract]   [Full Text] [Related]  

  • 11. The influence of a previous thalamotomy on the L-dopa effects on mono-manual dexterity in parkinsonism.
    Knutsson E; Mårtensson A; Meyerson BA; Risberg AM
    Scand J Rehabil Med; 1973; 5(3):130-3. PubMed ID: 4754551
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of L-dopa therapy in Parkinson's disease.
    Mones RJ; Elizan TS; Siegel GJ
    N Y State J Med; 1970 Sep; 70(18):2309-18. PubMed ID: 5272106
    [No Abstract]   [Full Text] [Related]  

  • 13. External work of walking and functional capacity in Parkinsonian patients treated with L-dopa.
    Gersten JW; Marshall C; Dillon T; Schneck SA; Orr W; Nelson C
    Arch Phys Med Rehabil; 1972 Dec; 53(12):547-53. PubMed ID: 4648427
    [No Abstract]   [Full Text] [Related]  

  • 14. Levodopa in parkinson's disease--Australian collaborative trial.
    Selby G
    Med J Aust; 1973 Mar; 1(12):577-85. PubMed ID: 4700544
    [No Abstract]   [Full Text] [Related]  

  • 15. [Evaluation of 12 months treatment with L-DOPA of patients with Parkinson's disease].
    van der Drift JH
    Ned Tijdschr Geneeskd; 1972 Nov; 116(48):2185-93. PubMed ID: 4639073
    [No Abstract]   [Full Text] [Related]  

  • 16. Physical therapy in Parkinson's disease: an open long-term rehabilitation trial.
    Pellecchia MT; Grasso A; Biancardi LG; Squillante M; Bonavita V; Barone P
    J Neurol; 2004 May; 251(5):595-8. PubMed ID: 15164194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study with cyclobenzaprine in idiopathic Parkinsonism.
    Korten JJ; van Hemert J
    Psychiatr Neurol Neurochir; 1973; 76(2):119-28. PubMed ID: 4700930
    [No Abstract]   [Full Text] [Related]  

  • 18. Using the Internet to assess activities of daily living and hand function in people with Parkinson's disease.
    Hoffmann T; Russell T; Thompson L; Vincent A; Nelson M
    NeuroRehabilitation; 2008; 23(3):253-61. PubMed ID: 18560142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
    Rascol O; Fabre N; Blin O; Poulik J; Sabatini U; Senard JM; Ané M; Montastruc JL; Rascol A
    Mov Disord; 1994 Jul; 9(4):437-40. PubMed ID: 7969211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Utility of L-dopa in the treatment of Parkinson's disease and parkinsonism-like diseases].
    Herskovits E; Matera R; Gacitua EF
    Medicina (B Aires); 1972; 32(1):10-4. PubMed ID: 5019629
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.